Clinical Trial Update: Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating Ravidasvir with Danoprevir/r and ribavirin in treatment-naive, non-cirrhotic chronic hepatitis C genotype 1 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Danoprevir/r (danoprevir/ritonavir)
• Ravidasvir (ravidasvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: HCV | Phase 2, Phase 3 | Status: COMPLETED